Possible impact of very late onset disease on clinical presentation and myasthenic crisis in myasthenia gravis
Abstract
Background: Myasthenia Gravis (MG) is an autoimmune disease marked by postsynaptic dysfunction at the neuromuscular junction. It usually shows a bimodal age distribution, with early- and late onset peaks. More recently, some authors have proposed a very late onset subgroup (≥65 years)- VLOMG, though its clinical relevance and prognostic implications remain uncertain. Objective: To assess the clinical and epidemiological characteristics of patients with very late-onset disease in our center. Methods: A retrospective cross-sectional study was conducted through a review of medical records of MG patients followed at the Neuromuscular Diseases Unit of Neurology Department of the Hospital Geral de Fortaleza (HGF) a tertiary reference unit sited at Northeast of Brazil. Clinical, serological and epidemiological characteristics were analyzed, and patients were classified by age at onset: juvenile (<18 years), early (18–49 years), late (50–64 years), and very late (≥65 years). Results: Among 175 MG patients, 48 (27%) were aged ≥65 years. Most were female (56%), anti AChR–positive (75%), and had generalized disease (85%). Among patients who developed a myasthenic crisis, 37% were from VLOMG group. There is no cases of thymoma in VLOMG group. Conclusion: VLOMG patients are sometimes described in the literature as having clinical and epidemiological features similar to those with early- and late-onset disease, although other authors report conflicting findings. In our study, we observed a higher proportion of women and a greater frequency of myasthenic crisis in this group, the latter likely reflecting a heavier disease burden early in the course of illness and/or the influence of associated comorbidities.